AFFILIATIONS
1 Institute for Immunology and Immune Health, Philadelphia, Pennsylvania, United States, Parker Institute for Cancer Immunotherapy, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Institute for Immunology and Immune Health, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 Center for Cellular Immunotherapies, Philadelphia, Pennsylvania, United States, Lymphoma Program, Philadelphia, Pennsylvania, United States
4 Institute for Immunology and Immune Health, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 Institute for Immunology and Immune Health, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 Institute for Immunology and Immune Health, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 Institute for Immunology and Immune Health, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 Institute for Immunology and Immune Health, Philadelphia, Pennsylvania, United States, Parker Institute for Cancer Immunotherapy, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 Center for Cellular Immunotherapies, Philadelphia, Pennsylvania, United States, Lymphoma Program, Philadelphia, Pennsylvania, United States
10 Institute for Immunology and Immune Health, Philadelphia, Pennsylvania, United States, Parker Institute for Cancer Immunotherapy, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
11 Center for Cellular Immunotherapies, Philadelphia, Pennsylvania, United States, Institute for Immunology and Immune Health, Philadelphia, Pennsylvania, United States, Lymphoma Program, Philadelphia, Pennsylvania, United States, Parker Institute for Cancer Immunotherapy, Philadelphia, Pennsylvania, United States
ABSTRACT
Introduction. T cell-based therapies, such as adoptive T cell transfer and checkpoint blockade, have transformed cancer treatment, yet their efficacy remains limited by intrinsic T cell dysfunction. T cells acquire this dysfunctional state through a dynamic and heterogenous series of differentiation decisions, regulated in part by epigenetic constraints, including chromatin accessibility. The SWItch/Sucrose-Non-Fermentable (SWI/SNF) family of chromatin remodeling complexes has been repeatedly implicated as modulators of T cell differentiation, and genetic deletion of SWI/SNF subunits improves adoptive T cell therapies against cancer. However, complete deletion of subunits causes global disruptions to SWI/SNF complex assembly that may obscure the many functions of this large ubiquitous complex and its components. In contrast, introduction of targeted mutations could enable deeper interrogation of the distinct roles of individual subunits. Therefore, there is: 1) a gap in our understanding of how mutations in SWI/SNF components influence T cell differentiation and function and 2) unexplored potential for translation to T cell therapies.
T cell neoplasms naturally select for mutations that enhance T cell survival. Within SWI/SNF complexes, the ATPase module SMARCA4 is mutated in 4% of T-ALLs, up to 14% in the TLX3 subtype. These mutations are largely missense mutations clustered in the ATPase and DNA-binding domains, suggesting a selective benefit to these mutations that affect catalytic function but keep the protein intact. We therefore hypothesize that introducing these cancer-associated mutations to Smarca4 in T cells can enhance their fitness in response to infection and cancer.
Methods and results. To test this hypothesis, we built a library of adenine base editor (ABE) guide RNAs targeting residues in murine Smarca4 identified from mutations in various cancers. Using the lymphocytic choriomeningitis virus (LCMV) model of T cell dysfunction, LCMV-specific mouse CD8 T cells (P14 cells) were retrovirally transduced with the guide library, followed by electroporation with ABE-expressing mRNA and transfer into recipient mice infected with LCMV. On day 15 post infection, we harvested spleens and sorted donor P14 cells by subset markers, isolated genomic DNA, and sequenced integrated guides for enrichment.
We observed significant enrichment of multiple guides targeting the T1156A mutation across both effector and non-effector subsets. We also observed non-effector subset-specific enrichment of a guide targeting the L550P mutation (all FDR<1e-4). Individual validation of our hit mutations by congenic mismatch co-transfer into acute LCMV-infected mice confirmed that T1156A increased the total number of P14 cells by 4.7-fold (p=0.001) and that L550P increased P14 numbers by 3-fold (p=0.001). The T1156A mutation skewed the distribution of differentiated subsets, increasing the number of effector cells by 6.5-fold (p=1e-4) as opposed to memory precursor cells by only 2.4-fold (p=0.008). In contrast, L550P-edited P14s expressed a lower frequency of effector and memory markers, leading to an 8.8-fold increase in cells not belonging to either subset (p=2e-5). In chronic infection, T1156A and L550P increased P14 cell expansion by 5-fold (p=0.008) and 3.9-fold (p=0.008) respectively. Moreover, T1156A-edited P14 cells achieved a higher frequency of IFNγ production after ex vivo peptide stimulation, with a 1.24-fold increase in the percentage of P14 cells able to express IFNγ compared to mock edited P14 cells (p=0.03).
Finally, we found that Smarca4-mutant murine CART19 improved in vitro tumor control against the A20 murine B-cell lymphoma cell line. CART19 cells edited with the T1156A mutation demonstrated improved 120-hour cytotoxicity at 0.25:1 and 0.125:1 effector:target ratios (p=0.03 and p=0.04) compared to CART19 edited with a control guide.
Conclusion. In summary, we identified key Smarca4 missense mutations in the DNA binding domain (T1156A) and a non-catalytic domain (L550P) that increased total T cell numbers, altered differentiation, and enhanced IFNγ production, resulting in improved responses against both in vivo viral infection and in vitro CAR T cell anti-tumor models. These data highlight the use of base editing mutagenesis to not only interrogate the role of chromatin remodelers in T cell function and differentiation decisions, but also to screen for beneficial cancer-associated mutations to improve T cell therapies.